RETEVMO 120 mg/1
selpercatinib · TABLET, COATED · Eli Lilly and Company
No Recall History
Plain English
RETEVMO is a tablet, coated containing selpercatinib at 120 mg/1, taken oral. Manufactured by Eli Lilly and Company.
Key Facts
- Brand Name
- RETEVMO
- Generic Name
- selpercatinib
- NDC Code (Product)
0002-6120- Manufacturer
- Eli Lilly and Company
- Strength
- 120 mg/1
- Dosage Form
- TABLET, COATED
- Route
- ORAL
- Marketing Status
- Application #
- NDA218160
- Drug Class
- Kinase Inhibitor [EPC]
- Marketing Start
- 04/10/2024
Recall History
No Recall HistoryFrequently Asked Questions
What is RETEVMO used for?
RETEVMO contains selpercatinib. It is a tablet, coated taken oral. Consult your doctor for specific uses.
Is RETEVMO a controlled substance?
RETEVMO is not classified as a controlled substance by the DEA.
What is the generic name for RETEVMO?
The generic name for RETEVMO is selpercatinib. There are no other listed brand versions of selpercatinib.
What is the NDC code for RETEVMO 120 mg/1?
The NDC (National Drug Code) for RETEVMO 120 mg/1 is 0002-6120, listed by Eli Lilly and Company.
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)